𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation?

✍ Scribed by Stefan A Brugger; Christian Oesterreicher; Peter Kalhs; Hildegard T Greinix; Christian Müller

Book ID
119502889
Publisher
The Lancet
Year
1997
Tongue
English
Weight
18 KB
Volume
349
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clearance of hepatitis B surface antigen
Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer
✍ G K Lau; A S Lok; R H Liang; C L Lai; E K Chiu; Y L Lau; S K Lam 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 1 views

Resolution of acute hepatitis B virus (HBV) infection re-Adoptive immunity transfer has been reported to be quires adequate B-and T-cell responses, which lead to the effective in clearing chronic hepatitis B virus (HBV) inproduction of protective antibodies, as well as a broad-based fection. Two hun

Adoptive transfer of immunity to hepatit
Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors
✍ Daniel Shouval; Ruth Adler; Yaron Ilan 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 589 KB

Recipients of allogeneic bone marrow transplantation are immunosuppressed as a result of their primary disease and by myeloablative therapy. Such patients are dependent on multiple blood products and are at risk for hepatitis B v i r u s infection. Active immunization against hepatitis B in the imme

Adoptive transfer of immunity to hepatit
Adoptive transfer of immunity to hepatitis B virus after T cell–depleted allogeneic bone marrow transplantation
✍ Yaron Ilan; Arnon Nagler; Ruth Adler; Elizabeth Naparstek; Reuven Or; Shimon Sla 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

Recipients of allogeneic bone marrow transplantation are pancytopenic for several weeks and immunosuppressed for many months as a result of myeloablative therapy required to eliminate the basic disease and to prevent allograft rejection. After bone marrow transplantation, these patients remain profo